Media thread, page-294

Unfortunately, the history of burnt Capital and failed trials has made MSB something of an anti-pattern for biotech investment to the point where (rather than providing any assistance to OCC) there's the potential for contamination by association. Some Australian MSB investors may now be sufficiently burnt to avoid all biotech moving forward.

It might be best for all concerned if any further progress/trials/management of the stem cell technology currently within MSB was taken forward methodically under a new commercial structure in something of a fresh start.

In contrast, notwithstanding the lack of updates from time to time I've found communications from OCC management relatively straightforward and methodical (and supported by some seemingly astute recruitment).

There's no guarantee of success but I'm much more comfortable with the seemingly greater method and respect for Capital over here. Very much the tortoise and the hare.